A Randomized Trial of Coartemether & Artekin for the Treatment of

Status Completed

Clinical Trial Summary

This open randomized, parallel group, 6 week trial in two rural outpatient clinics will compare the safety and efficacy of a six dose coartemether regimen with 3 dose artekin regimen for the treatment of acute, uncomplicated falciparum and vivax malaria in adults and children (>10kg).

Clinical Trial Description

With the emergence of species of multi drug resistant P.falciparum across the archipelago the Indonesian Centre for Disease Control (CDC) now recommends amodiaquine plus artesunate in areas of high chloroquine and sulfadoxine-pyrimethamine resistant strains of P. falciparum. High levels of chloroquine resistance to P.vivax has also emerged in the eastern provinces.

This trial sets out to assess two fixed dose artemisinin combination regimens: artekin (DHA-Piperaquine) and coartemether (artemether-lumefantrine) against both P.falciparum and P. vivax and their safety profiles.

Patients who present to an established rural outpatient clinic in Timika, Papua with symptoms of acute, uncomplicated infection with P. falciparum, P.vivax or both species, will after laboratory confirmation of the diagnosis and having given informed consent to participate in the trial, be enrolled in the study. Drug administration will be supervised once per day. Patients will be treated as out-patients and then seen daily for the first week until aparasitaemic and thereafter at weekly visits to the clinic.

The data used from this trial will be used to make a public health decision to determine a suitable alternative first line antimalarial in the Timika region. In order to ensure that the data gathered will be relevant to the clinical setting in which the drugs will be used, drug administration of medication will be deliberately designed to mimic conditions that will be experienced with widespread deployment (eg once daily supervision). ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00157833
Study type	Interventional
Source	Menzies School of Health Research
Contact
Status	Completed
Phase	N/A
Start date	July 2004
Completion date	August 2005

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01625871` - Artemether/Lumefantrine and Vivax Malaria	Phase 3
Completed	`NCT02876549` - G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria	Phase 4
Completed	`NCT01218932` - Pharmacokinetic Study of Primaquine and Chloroquine in Healthy Subjects	Phase 1
Recruiting	`NCT04228315` - Biomarkers of P. Vivax Relapse	N/A
Completed	`NCT02118090` - Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia:	Phase 4
Completed	`NCT01074905` - Study on the Treatment of Vivax Malaria	Phase 3
Completed	`NCT04222088` - TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014
Completed	`NCT01546961` - Chloroquine Population Pharmacokinetics in Pre and Post-partum Women	N/A
Completed	`NCT00158548` - ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan	Phase 3
Completed	`NCT00682578` - A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan	Phase 3
Active, not recruiting	`NCT03529396` - Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients	Phase 2
Recruiting	`NCT05874271` - Short Course Primaquine for the Radical Cure of P. Vivax - Papua New Guinea	N/A
Completed	`NCT05958797` - TES of Chloroquine for Pv in the Philippines in 2016
Completed	`NCT01716260` - Safety and Efficacy of Chloroquine and Primaquine for Vivax Malaria in Bhutan	N/A
Completed	`NCT01288820` - Study of ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria	Phase 3
Completed	`NCT01640574` - Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD)	Phase 3
Completed	`NCT01076868` - Incidence of Vivax Along the Thai Burma Border	N/A
Completed	`NCT00158561` - Chlorproguanil/Dapsone Compared With Chloroquine and SP for Vivax Malaria	Phase 3
Completed	`NCT01780753` - Primaquine Pharmacokinetics in Lactating Women and Their Infants	Phase 1
Completed	`NCT06044805` - Therapeutic Efficacy of Chloroquine Plus Primaquine in the Treatment of Uncomplicated Plasmodium Vivax	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Randomized Trial of Coartemether and Artekin for the Treatment of Uncomplicated Malaria in Papua, Indonesia.

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms